AHCL/ SE/35/2026-27 **November 3, 2026**

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	**BSE Limited** Department of Corporate Services 1st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
Symbol: AMRUTANJAN	**Scrip Code: 590006**

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **3rd November 2026** had inter-alia:

(i) Approved the Unaudited Financial Results for the quarter and half year ended September 30, 2026, as recommended by the Audit Committee at its meeting held today 3rd November 2026, the same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.

(ii) Declared First Interim Dividend of Re.1/- per share for the financial year 2026-27 on the Equity Shares of the Company.

The Board Meeting commenced at 12:00 P.M and concluded at 6.00 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For **Amrutanjan Health Care Limited**

GAGAN PREET SINGH

Digitally signed by GAGAN PREET SINGH
Date: 2026.11.03 18:04:57 +05'30'

Gagan Preet Singh
General Manager - Legal
Company Secretary and Compliance Officer

Encl:
1. Un-audited Standalone Financials Results for the quarter ended September 30, 2026
2. Limited Review Report

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Note 1: Statement of assets and liabilities

(Amount in INR in Lakhs)

S. No.	Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
A	**ASSETS**		
1	**Non-current assets**		
	(a) Property, plant and equipment	15,833.14	4,829.93
	(b) Right-of-use assets	1,074.22	150.81
	(c) Capital work in progress	1,947.37	10,547.98
	(d) Intangible assets	136.78	144.75
	(e) Intangible assets under development	23.70	23.70
	(f) Financial assets		
	Investments	4.11	4.67
	Other financial assets	690.36	4,619.09
	(g) Deferred tax assets (net)	253.31	531.46
	(h) Other tax assets (net)	536.69	290.56
	(i) Other non-current assets	493.19	581.53
	Total non-current assets	**20,992.87**	**21,724.48**
2	**Current assets**		
	(a) Inventories	5,808.60	3,735.04
	(b) Financial assets		
	(i) Investments	316.07	307.40
	(ii) Trade receivables	4,442.42	6,064.40
	(iii) Cash and cash equivalents	796.45	1,127.23
	(iv) Bank balances other than (iii) above	1,512.09	2,205.23
	(v) Other financial assets	15,923.57	14,234.00
	(c) Other current assets	1,716.72	1,491.32
	Total current assets	**30,515.92**	**29,164.62**
	Total assets (1+2)	**51,508.79**	**50,889.10**
B	**EQUITY AND LIABILITIES**		
1	**Equity**		
	(a) Equity share capital	289.11	289.11
	(b) Other equity	38,104.80	36,734.15
	Total equity	**38,393.91**	**37,023.26**
	Liabilities		
2	**Non-current liabilities**		
	(a) Financial liabilities		
	Lease liabilities	152.45	142.32
	Other financial liabilities	55.27	103.06
	(b) Provisions	1,074.54	1,002.01
	Total non-current liabilities	**1,282.26**	**1,247.39**
3	**Current liabilities**		
	(a) Financial liabilities		
	Lease liabilities	36.56	35.42
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	447.70	337.50
	total outstanding dues of creditors other than micro enterprises and small enterprises	5,891.17	6,752.00
	Other financial liabilities	3,836.57	2,936.74
	(b) Other current liabilities	718.16	992.85
	(c) Provisions	330.40	1,056.68
	(d) Current tax liabilites (net)	572.06	507.26
	Total current liabilities	**11,832.62**	**12,618.45**
	Total liabilities (2+3)	**13,114.88**	**13,865.84**
	Total equity and liabilities (1+2+3)	**51,508.79**	**50,889.10**

AMRUTANJAN HEALTH CARE LTD. MYLAPORE, CHENNAI-4

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Note 2: Statement of Cash flows

(Amount in INR in Lakhs)

Particulars	For the half year ended 30 September 2026 (Unaudited)	For the half year ended 30 September 2025 (Unaudited)	For the year ended 31 March 2026 (Audited)
Cash flow from operating activities			
Profit before tax	2,916.53	3,050.76	7,788.78
Adjustments for:			
Depreciation and amortisation expense	540.57	308.84	631.90
Loss / (Profit) on sale of property, plant and equipment	1.79	(10.38)	(10.38)
Equity-settled share-based payment transactions	47.32	87.88	(93.42)
Loss allowance on trade receivables	118.45	43.20	91.52
Bad debts written off	-	0.15	0.15
Change in fair value of financial assets at FVTPL	(8.11)	0.18	(7.56)
Interest income on cash and cash equivalents and other bank balances	(516.97)	(738.26)	(1,473.71)
Interest income on corporate debt securities and loans at amortised cost	(73.46)	(79.15)	(118.33)
Excess provision written back, net	(33.92)	(21.22)	(107.20)
Gain on surrender of lease	(1.92)	-	-
Finance costs	8.86	10.12	19.50
Operating profit before working capital / other changes	**2,999.14**	**2,652.12**	**6,721.25**
Working capital adjustments:			
Decrease / (Increase) in trade receivables	1,503.53	1,708.45	(573.89)
(Increase) in other assets	(239.38)	(266.19)	(904.87)
(Increase) in other financial assets	(41.80)	(11.29)	(50.95)
(Increase) in inventories	(2,073.56)	(824.13)	(1,009.06)
(Decrease) in other financial liabilities	(60.75)	(68.75)	-
(Decrease) / Increase in provisions	(657.53)	74.17	976.65
(Decrease) / Increase in trade payables	(716.71)	(1,082.70)	292.43
(Decrease) / Increase in other liabilities	(274.69)	(216.18)	48.28
	(2,560.89)	**(686.62)**	**(1,221.41)**
Cash generated from operating activities	**438.25**	**1,965.50**	**5,499.84**
Less: Income tax paid (net)	(654.20)	(874.78)	(1,903.07)
Net cash (used in) / generated from operating activities (a)	**(215.95)**	**1,090.72**	**3,596.77**
Cash flows from investing activities			
Purchase or construction of property, plant and equipment, intangible assets, capital work-in progress, intangible assets under development, right of use assets, movement in capital advances and payable towards purchase of property, plant and equipment (including retention payable)	(3,648.39)	(1,872.88)	(5,500.38)
Proceeds from sale of Property, plant and equipment	0.41	10.38	10.38
Redemption / (Investment) in bank deposits and financial institutions	3,800.33	486.29	2,075.09
Interest received on deposits with banks and financial institutions, net	590.43	554.60	1,592.04
(Investments made) / Proceeds from redemption of investments	-	-	(300.00)
Net cash generated from / (used in) investing activities (b)	**742.78**	**(821.61)**	**(2,122.87)**
Cash flow from financing activities			
Dividend paid	(832.32)	(751.68)	(1,319.80)
Sale of shares by employee stock option trust	-	6.95	7.18
Payment of lease liabilities	(25.29)	(24.68)	(49.57)
Net cash (used in) financing activities (c)	**(857.61)**	**(769.41)**	**(1,362.19)**
Net change in cash and cash equivalents (a) + (b) + (c)	**(330.78)**	**(500.30)**	**111.71**
Cash and cash equivalents at the beginning of the year	1,127.23	1,015.52	1,015.52
Effect of exchange rate fluctuations on cash held	-	-	-
Cash and cash equivalents at the end of the period	**796.45**	**515.22**	**1,127.23**
Components of cash and cash equivalents			
Cash on hand	4.33	4.87	3.06
Bank balances	792.12	510.35	1,124.17
Cash and cash equivalents as per Statement of assets and liabilities	**796.45**	**515.22**	**1,127.23**

Note: The above cash flow statement has been prepared under the "indirect method" as set out in the Ind AS 7 on statement of Cash Flows specified under section 133 of the Companies Act, 2013

AMRUTANJAN HEALTH CARE LTD. MYLAPORE, CHENNAI-4

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter and half year ended 30 September 2026

(Amount in INR in Lakhs)

	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
I	Revenue from operations	13,517.89	10,296.88	11,770.02	23,814.77	21,174.59	50,255.27
II	Other income	301.88	381.48	429.63	683.36	872.37	1,757.39
III	**Total income (I + II)**	**13,819.77**	**10,678.36**	**12,199.65**	**24,498.13**	**22,046.96**	**52,012.66**
IV	**Expenses**						
	(a) Cost of materials consumed	4,671.91	2,575.86	2,512.38	7,247.77	4,636.01	10,642.70
	(b) Purchase of stock-in-trade	1,753.90	3,608.00	3,519.07	5,361.90	6,635.34	14,063.09
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(353.13)	(755.96)	(265.95)	(1,109.09)	(566.83)	(269.64)
	(d) Employee benefits expense	1,799.65	1,762.42	1,595.08	3,562.07	3,196.39	6,376.25
	(e) Finance cost	4.47	4.39	4.97	8.86	10.12	19.50
	(f) Depreciation and amortisation expense	349.05	191.52	155.77	540.57	308.84	631.90
	(g) Other expenses						
	- Advertisement and selling expenditure	1,464.50	781.39	1,374.95	2,245.89	2,111.89	6,003.83
	- Others	1,819.83	1,701.05	1,381.89	3,520.88	2,664.44	5,870.58
	Total expenses (IV)	**11,510.18**	**9,868.67**	**10,278.16**	**21,378.85**	**18,996.20**	**43,338.21**
V	**Profit before exceptional item & tax (III - IV)**	**2,309.59**	**809.69**	**1,921.49**	**3,119.28**	**3,050.76**	**8,674.45**
VI	**Exceptional item**						
	Lease rent (refer Note 9)	-	202.75	-	202.75		760.50
	Impact of New labour codes (refer Note 10)	-	-	-	-		125.17
VII	**Profit before tax (V - VI)**	**2,309.59**	**606.94**	**1,921.49**	**2,916.53**	**3,050.76**	**7,788.78**
VIII	Tax expenses	581.60	170.37	525.33	751.97	823.48	1,997.00
IX	**Profit after tax (V - VI)**	**1,727.99**	**436.57**	**1,396.16**	**2,164.56**	**2,227.28**	**5,791.78**
X	**Other comprehensive income / (loss)**						
	Items that will not be reclassified subsequently to profit or loss						
	Re-measurement gain/(loss) on defined benefit plans	**42.71**	(46.49)	(26.08)	(3.78)	(33.60)	(18.50)
	Income tax relating to items that will not be reclassified to profit or loss	(10.75)	11.70	6.57	0.95	8.46	4.66
	Other comprehensive income/ (loss), net of taxes	**31.96**	**(34.79)**	**(19.51)**	**(2.83)**	**(25.14)**	**(13.84)**
XI	**Total comprehensive income for the period / year (VII + VIII)**	**1,759.95**	**401.78**	**1,376.65**	**2,161.73**	**2,202.14**	**5,777.94**
	Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11	289.11
	Other equity						36,734.15
	Earnings per equity share						
	Basic earnings per share (INR)	5.98	1.51	4.83	7.49	7.70	20.03
	Diluted earnings per share (INR)	5.98	1.51	4.83	7.49	7.70	20.03
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

See accompanying notes to Unaudited financial results

AMRUTANJAN HEALTH CARE LTD. MYLAPORE, CHENNAI-4

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

3. The above unaudited financial results for the quarter and half year ended 30 September 2026 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 3 November 2026. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.

4. These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

5.The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.

6. The shareholders of the Company at its Annual General Meeting held on 23 September 2026, has approved final dividend of INR 2.90/- per equity share of face value INR 1/- each for the financial year ended 31 March 2026.

7. The Company has declared First Interim Dividend of INR.1/- per share aggregating to INR 289.11 lakhs for the financial year 2026-27

8.During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024. The Compensation Committee has withdrawn the "ESOP 2 Scheme" due to non – satisfaction of vesting conditions (Turnover) and unfavorable movement in the market price of the shares. In line with Ind AS 102, the impact of such cancellation amounting to INR 269.16 Lakhs is recognised in the Statement of Profit and Loss during the year end 31 March 2026 such that the cumulative expense reflects the cost of vested options, with a corresponding adjustment to share based payment reserve. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved the further grants under the scheme mentioned above as "Second Phase ESOP 2 Scheme", at its meeting held on 7 May 2026.

9.During the financial year 2005-06, the Government of Tamil Nadu retrospectively revised the lease rent for a leasehold land, effective from November 2001, by determining fair rent under Section 34A of the Tamil Nadu Hindu Religious and Charitable Endowments Act, 1959 (HR & CE Department). Pursuant to this revision, a demand notice was issued to the Company. Accordingly, the Company had filed a Writ Petition before the High Court of Judicature, Madras challenging the fair rent determination, contending that the revision was exorbitant and not legally tenable. On 25 September 2025, the High Court of Judicature, Madras dismissed the petition and upheld the rent fixed by the Fair Rent Committee constituted by the Government of Tamil Nadu. Based on the advice from the external consultant, the Company filed an appeal on 9 December 2025 before the Division Bench of the High Court of Judicature, Madras and the appeal was dismissed on 16 March 2026. Further, the Company filed a review petition against the said appeal and the same was also dismissed on 30 April 2026. Accordingly, the Company has created a provision for INR 760.50 lakhs for the year ended 31 March 2026. However, In July 2026, the Company has received a demand notice from HR & CE Department for INR 974.67 lakhs with arrears.Management settled the demand on 1 August 2026, resulting in an additional cost of INR 202.75 lakhs, disclosed as an exceptional item for the quarter ended 30 June 2026.The Company received the full and final settlement letter on 03 August 2026. The letter confirmed that the attachment over the property had been completely withdrawn. The possession of the land was handed over in May 2018.

10.Effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising four labour codes collectively referred to as the 'New Labour Codes'. Under Ind AS 19, changes to the employee benefit plans arising from legislative amendments constitute a plan amendment, requiring recognition of past service cost immediately in the Statement of Profit and Loss. The New Labour Codes has resulted in estimated one time increase in provision of employee benefits of the Company of INR 125.17 Lakhs and the same has been recognised as "Exceptional item" during the year ended 31 March 2026. The Company has considered restructured compensation of its employees with effect from July 2026 consistent with the Labour Codes & rules.

11. The unaudited financial results of the Company for the quarter and half year ended 30 September 2026 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.

AMRUTANJAN HEALTH CARE LTD. MYLAPORE, CHENNAI-4

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

12. **Segment reporting in the Unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segment (represents Pain Management Centre), pursuant to launch of New products Women's Hygiene is renamed as Women's Hygiene & Personal Care.

(Amount in INR in Lakhs)

	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2026 (Unaudited)	30 June 2026 (Unaudited)	30 September 2025 (Unaudited)	30 September 2026 (Unaudited)	30 September 2025 (Unaudited)	31 March 2026 (Audited)
1	**Segment revenue**						
a	OTC Products	9,093.76	5,725.83	8,001.84	14,819.59	13,699.08	32,831.73
b	Women's Hygiene & Personal Care	4,048.22	3,635.77	3,278.04	7,683.99	6,138.79	13,990.66
c	Beverages	302.67	863.59	428.84	1,166.26	1,204.85	3,156.09
d	Others	73.24	71.69	61.30	144.93	131.87	276.79
	Total	**13,517.89**	**10,296.88**	**11,770.02**	**23,814.77**	**21,174.59**	**50,255.27**
2	**Segment results**						
a	OTC Products	2,328.91	987.44	1,841.04	3,316.35	2,920.18	8,344.36
b	Women's Hygiene & Personal Care	46.19	(287.61)	(125.74)	(241.42)	(110.89)	(272.16)
c	Beverages	(241.24)	(125.98)	(64.87)	(367.22)	(364.69)	(634.86)
d	Others	14.17	3.39	(15.10)	17.56	(19.61)	(27.64)
	Total	**2,148.03**	**577.24**	**1,635.33**	**2,725.27**	**2,424.99**	**7,409.70**
	Less: Finance cost	4.47	4.39	4.97	8.86	10.12	19.50
	Add: Interest income net of other unallocable expenditure	166.03	34.09	291.13	200.12	635.89	398.58
	Total profit before tax	**2,309.59**	**606.94**	**1,921.49**	**2,916.53**	**3,050.76**	**7,788.78**
3	**Segment assets**						
a	OTC Products	9,090.70	8,307.90	7,027.96	9,090.70	7,027.96	7,897.10
b	Women's Hygiene & Personal Care	17,097.29	15,007.23	6,877.07	17,097.29	6,877.07	13,593.47
c	Beverages	2,239.13	2,672.87	2,566.63	2,239.13	2,566.63	3,376.12
d	Others	18.67	130.72	126.35	18.67	126.35	120.38
e	Unallocated assets	23,063.00	24,185.26	26,637.81	23,063.00	26,637.81	25,902.03
	Total	**51,508.79**	**50,303.98**	**43,235.82**	**51,508.79**	**43,235.82**	**50,889.10**
4	**Segment liabilities**						
a	OTC Products	5,998.19	5,298.83	5,190.02	5,998.19	5,190.02	5,726.00
b	Women's Hygiene & Personal Care	4,786.96	4,569.89	1,673.34	4,786.96	1,673.34	4,739.52
c	Beverages	392.23	994.75	690.98	392.23	690.98	1,576.29
d	Others	38.80	50.51	65.64	38.80	65.64	36.90
e	Unallocated liabilities	1,898.70	1,941.28	1,409.07	1,898.70	1,409.07	1,787.13
	Total	**13,114.88**	**12,855.26**	**9,029.05**	**13,114.88**	**9,029.05**	**13,865.84**
	Total capital employed in the Company	**38,393.91**	**37,448.72**	**34,206.77**	**38,393.91**	**34,206.77**	**37,023.26**

For Amrutanjan Health Care Limited

S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Date: 03 November 2026
Place: Chennai

B S R & Co. LLP
Chartered Accountants

KRM Tower, 1st and 2nd Floors
No. 1, Harrington Road, Chetpet
Chennai – 600 031, India
Telephone: +91 44 4608 3100
Fax: +91 44 4608 3199

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 30 September 2026 and year to date results for the period from 1 April 2026 to 30 September 2026 ("the Statement") in which are included unaudited financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP trust").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

R Kalyana Sundara Rajan
Partner
Membership No.: 221822
UDIN:26221822WVBVRO7314

Chennai
03 November 2026